Document is current

Article History

Received: 9 October 2022

Accepted: 20 February 2023

First Online: 28 February 2023

Declarations

:

: The study protocol was approved by each center’s institutional review board or independent ethics committee (Beijing Anzhen Hospital, Capital Medical University [2019-15]; General Hospital of Ningxia Medical University [2019-YW-063]; The First Affiliated Hospital of Xinjiang Medical University [D190924-01]; The First Hospital of China Medical University [2019YL071]; Inner Mongolia Autonomous Region People's Hospital [YWLCSYLL2019-021-01]; Lanzhou University First Hospital [2019-41]; Tianjin Medical University General Hospital [IRB2019-189-01]; Shanxi Cardiovascular Hospital [YL-LL-AF-043]; Hainan Provincial People’s Hospital [2019-190]; The First Affiliated Hospital of Sun Yat-Sen University [2019-046-01]; The First Affiliated Hospital of Dalian Medical University [PJ-KS-JG-YW-2019-212(X)]; The First Affiliated Hospital of Henan University of Science and Technology [2019-0061]; Peking University First Hospital [2019-62]; Qilu Hospital, Shandong University [2019071]; Shenzhen People’s Hospital [SYL-201943-02]; The Second Xiangya Hospital, Central South University [2019-107]; Xiamen University Cardiovascular Hospital [2019-6]; The Fourth Affiliated Hospital of Harbin Medical University [2019-050]; The First Affiliated Hospital of Soochow University [2019-143]; Jiangsu Provincial People’s Hospital [2019-MD-490]; The First Affiliated Hospital of Zhengzhou University [2019-163]; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology [2019-331]). This study was conducted in accordance with the principles of Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. All participants provided written informed consent prior to screening.

: Not applicable.

: YZ, MC, YH, WZ, XH, GZ, XM, PQ, DS, YL an WH report personal fees from Innovent Biologics, Inc., during the conduct of the study. PA, HL, SY, QM, HD and LQ were employees of Innovent Biologics, Inc.